2020
DOI: 10.1101/2020.06.02.130674
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α

Abstract: Aging is the greatest risk factor for most chronic diseases. Metabolic dysfunction underlies several chronic diseases, which are further exacerbated by obesity. Dietary interventions can reverse metabolic declines and slow aging processes, although compliance issues remain paramount due to adverse effects on quality of life.17α-estradiol treatment improves metabolic parameters and slows aging in male mice. The mechanism by which 17α-E2 elicits benefits remain unknown, which has led speculation that an uncharac… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
9
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2
1

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(10 citation statements)
references
References 154 publications
(181 reference statements)
1
9
0
Order By: Relevance
“…To investigate the effects of 17α-E2 on the development of liver fibrosis in mice, we administered CCl 4 to induce hepatotoxic stress while also providing 17α-E2 for the entire duration of the eight-week study (preventive group) or the final four weeks of the study (therapeutic group). Consistent with our previous reports 40-43,46,67,68 , 17α-E2 treatment reduced body mass at the conclusion of the study in both the preventive and therapeutic groups ( Fig. 2a ).…”
Section: Resultssupporting
confidence: 93%
See 2 more Smart Citations
“…To investigate the effects of 17α-E2 on the development of liver fibrosis in mice, we administered CCl 4 to induce hepatotoxic stress while also providing 17α-E2 for the entire duration of the eight-week study (preventive group) or the final four weeks of the study (therapeutic group). Consistent with our previous reports 40-43,46,67,68 , 17α-E2 treatment reduced body mass at the conclusion of the study in both the preventive and therapeutic groups ( Fig. 2a ).…”
Section: Resultssupporting
confidence: 93%
“…We and others have since reported that 17α-E2 treatment reduces adiposity and improves a myriad of systemic metabolic parameters in obese and old male mice without inducing overt feminization 40-45 . In liver, 17α-E2 dramatically reduces steatosis and age-related DNA damage, while also significantly improving hepatic insulin sensitivity in an ERα-dependent manner 40,46 . We also found that 17α-E2 attenuates several histological and transcriptional markers of liver fibrosis in models of diet-induced obesity 46 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…17a-estradiol treatment might alleviate some neurodegenerative disorders and has been shown to extend lifespan in mice and reduce metabolic dysfunction. [148][149][150] This steroid might be an intervention option for long-term impacts of COVID. Ketogenic diets and ketogenic agents reduce fat mass and obesity, one of the major risk factors for COVID-19 complications.…”
Section: And Dietary Interventions (Fig 2)mentioning
confidence: 99%
“…82,83 17a-estradiol levels decline with age and its replacement therapy; extends life span, reduces metabolic dysfunction, and improves some neurodegenerative diseases in mice. [84][85][86] Sirtuin agonists, eg, the polyphenol resveratrol, have antioxidant and antiinflammatory properties. 87 Ketogenic diets and ketone bodies can reduce adipose mass and obesity and might hold promise for alleviating age-and infection-induced morbidities.…”
Section: Pharmacologic Geroprotectorsmentioning
confidence: 99%